Renal cell carcinoma · line 1 · Pembrolizumab monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-PEMBROLIZUMAB-MONO`

ID	`IND-RCC-ADJUVANT-PEMBRO`
Type	Indication
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-ESMO-RCC-2024` `SRC-KEYNOTE-564-CHOUEIRI-2021` `SRC-NCCN-KIDNEY-2025`

Notes

Adjuvant pembrolizumab is the only systemic therapy with proven OS benefit post-nephrectomy in RCC (KEYNOTE-564 updated). Stage II high-risk (pT2G4), all stage III (pT3-4, N1), and M1-NED are the eligible groups. Stage I and low-risk stage II — observation only. Timing: must start ≤12 weeks post-surgery.

Used By

Algorithms

ALGO-RCC-METASTATIC-1L - ALGO-RCC-METASTATIC-1L